Skip to main content
Clinical Trials/NCT04854967
NCT04854967WithdrawnNot Applicable

Post-REcovery LIbEration From Oxygen in Exacerbated COPD (RELIEF)

VA Office of Research and Development1 site in 1 countryStarted: April 18, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Locations
1
Primary Endpoint
Discontinuation of Oxygen at 12 weeks

Study Overview

Brief Summary

The investigators want to decrease inappropriate oxygen use for patients with COPD. The investigators are testing a new program that will stop oxygen prescriptions for patients that no longer need it and will instead provide them with training in skills that have been shown to help patients breathe better. Participants will be randomly assigned to receive the intervention program or usual care. After 12 weeks the investigators will determine if the program helped stop unnecessary oxygen prescription. The investigators will also determine if health status, distance walked during six minutes, and symptoms of breathlessness after walking are different between participants who received the program and those who did not. The investigators will meet with participating patients and their providers after the study is complete to find out how they feel about this program and if it would be possible to put this change into practice.

Detailed Description

The purpose of this pilot study is to test an intervention designed to decrease inappropriate oxygen use for patients with COPD. Participants will be randomized to usual care vs. an oxygen de-implementation intervention. Patients assigned to the oxygen de-implementation intervention group will have their active oxygen prescription discontinued, be educated on pursed lip breathing and receive inhaler training. A follow-up assessment will occur at 12 weeks. The primary outcome at 12 weeks will be discontinuation of oxygen. Secondary outcomes include health status as measured by the Clinical COPD Questionnaire (CCQ), tele-six minute walk test (6MWT) distance, and Borg dyspnea scale assessed after the tele-6MWT. Among the intervention group, the investigators will also assess acceptability and feasibility of the intervention for patient participants and their providers.

Recruitment was expected to begin in November 2021 but was delayed due to the COVID-19 Omicron outbreak. Recruitment officially began on April 18, 2022.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
40 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age 40 years or older
  • •Diagnosis of COPD
  • •Discharged within the past 3 months after hospitalization for COPD exacerbation, CHF exacerbation and/or Pneumonia and Active prescription for supplemental oxygen within 48 hours of discharge that remains active; or Stable COPD with no chronic resting hypoxemia and an active prescription for supplemental oxygen.
  • •No inpatient or outpatient exacerbations of COPD within the last 30 days
  • •Smoked at least 10 pack-years of cigarettes
  • •Room air resting saturation >88% on room air
  • •Spirometry consistent with COPD (FEV1/FVC < 0.70) and/or evidence of emphysema on CT scan
  • •Willingness on the part of the participant to stop oxygen if randomized to the intervention
  • •Ability and willingness to participate in virtual video visits with study staff using VA approved software
  • •Informed consent for participation

Exclusion Criteria

  • •Desaturation during 6MWT <80% for one minute or more
  • •Non-COPD lung disease that affects oxygenation or survival (including pulmonary hypertension)
  • •Prescription of oxygen for alternative condition (e.g. bleed-in with positive airway pressure therapy for obstructive sleep apnea)
  • •Diagnosis expected to result in death in six months or enrollment in hospice
  • •Participation in another intervention trial
  • •Cognitive issues that would preclude participation (dementia, stroke, etc.)
  • •Residence in skilled nursing facility
  • •Inability to speak, read, or understand English
  • •Any safety concerns
  • •Participants clinical team excludes the participant from recruitment or evaluation

Arms & Interventions

De-implementation Intervention

Experimental

The oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an "unlearning" component targeting provider and patient education and 3) a "substitution" component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing).

Intervention: Rescind home oxygen order (Other)

De-implementation Intervention

Experimental

The oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an "unlearning" component targeting provider and patient education and 3) a "substitution" component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing).

Intervention: Provider Education (Behavioral)

De-implementation Intervention

Experimental

The oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an "unlearning" component targeting provider and patient education and 3) a "substitution" component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing).

Intervention: Patient Education (Behavioral)

De-implementation Intervention

Experimental

The oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an "unlearning" component targeting provider and patient education and 3) a "substitution" component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing).

Intervention: Teach-to-goal inhaler training (Behavioral)

De-implementation Intervention

Experimental

The oxygen de-implementation intervention will consist of: 1) an order to rescind the patient's home oxygen 2) an "unlearning" component targeting provider and patient education and 3) a "substitution" component that introduces alternative evidence-based therapies to treat dyspnea (e.g. teach-to-goal inhaler teaching and pursed lip breathing).

Intervention: Pursed lip breathing (Behavioral)

Usual Care

No Intervention

The patient receives usual care from their assigned clinical provider.

Outcomes

Primary Outcomes

Discontinuation of Oxygen at 12 weeks

Time Frame: 12 weeks

The investigators will assess the proportion of participants who have no active prescription for oxygen at 12 weeks.

Secondary Outcomes

  • tele-six minute walk test distance (tele-6MWT)(Through study completion, an average of 12 weeks)
  • Proportion of potentially eligible participants randomized(At study completion, an average of 12 weeks)
  • Rate of completion of all visits(Through study completion, an average of 12 weeks)
  • Proportion of participants completing tele-6MWT(At study completion, an average of 12 weeks)
  • Proportion of participants completing in-home spirometry(At study completion, an average of 12 weeks)
  • Acceptability to patients(At study completion, an average of 12 weeks)
  • Acceptability to providers(At study completion, an average of 12 weeks)
  • Post tele-six minute walk test (tele-6MWT) Borg Dyspnea scale(Through study completion, an average of 12 weeks)
  • Cost of intervention(At study completion, an average of 12 weeks)
  • Clinical COPD Questionnaire (CCQ) Total Score(Through study completion, an average of 12 weeks)
  • Proportion of randomized participants completing 12 week follow up(At study completion, an average of 12 weeks)

Investigators

Sponsor Class
Fed
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials